Aguilar RF

Language: Spanish
References: 29
Page: 62-69
PDF size: 128.67 Kb.

ABSTRACT

The human genoma project has been to know the human genetic code, and therefore the structure of the individual’s hereditary patrimony, what will allow maybe not in a future very distant to reach better therapeutic possibilities for the more prevalent illnesses in the world.

REFERENCES

1. Kresina TF. An introduction to molecular medicine and gene therapy. Wiley-Liss New Cork 2001:23-43.

2. Murray AW. Whiter genomics? Genome Biology 2000;1(1):31-36.

3. Tenant MR, Miyamoto MM. The role of medical libraries in undergraduate education: a case study in genetics. J Med Libr Assoc 2002;90(2):181-193.

4. Burke W. Genomics as a probe for disease biology. New Engl J Med 2003;349(10):969-974.

5. Ciarleglio LJ, Bennett RL, Williamson J, Mandell JB, Marks JH. Genetic counseling throughout the life cycle. J Clin Invest 2003;112:1280-1286.

6. Shi MM. Technologies for Individual genotyping detection of genetic polymorphism in drugs targestand disease genes. Am Pharmacogenomics 2002;2(3):197-205.

7. Guttmacher AE, Collins FS, Drazen JM. Genomic medicine. The John Hopkins University Press and the New England Journal of Medicine. 2004:402.

8. Green ED. The Human Genome Project. And its Impact On The Study of Human Disease. NISC 2003:201-211.

9. International Human Genome Sequencing Consortium. Initial sequencing and analysis of human genome. Nature 2001;409:860-921.

10. International SNP Map Working Group A map of human genome sequence variation containing 1.42 million single nucleotide polymorphism. Nature 2001;409:928-933.

11. International Human Genome Sequencing Consortium. Science Epigenetics 2001;293(5532):1001-1208.

12. Pagon RA. Genetic diagnosis and counseling. In: Dale Dc, Federman DD. Eds. Subsec VIII. New York NY: Scientific American. Inc Sci Am Med 2001;2(9):290-301.

13. Bird T. Risk and Benefits of DNA testing for Neurogenetic Disorders. Seminars in Neurology 1999;19:253-259.

14. Stankiewics P, Lupski JR. Genome architecture, rearrangements and genomic disorders. Trends Genet 2002;18(2):74-82.

15. Yu A, Zhao C, Fan Y et al. Comparison of human genetic and sequence-based physical maps. Nature 2001;409:951-953.

16. Merikangas KR, Risch N. Genomic Priorities and Public Health. Science 2003;302:599-601.

17. Meléndez-Herrada E. Cervantes-García E, Ramos-González MA, Cravioto A. Impacto de la genómica bacteriana en la medicina humana. Rev Fac Med UNAM 2005;48:18-23.

18. Brodrsossy L. Otigonucleotide microarray microbial diagnostic. Curr Opin Microbiol 2004;7:245-254.

19. Almeida-González L, Franco-Paredes C, Pérez LF, Santos-Preciado JI. Enfermedad por meningococo, Neisseria meningitidis: perspectiva epidemiológica, clínica preventiva. Salud Pública Mex 2004;46:428-450.

20. Matsuura T et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet 2000;26:191-194.

21. Kuokkanen S et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 1997;61:1379-87.

22. Roses AD. A model for susceptibility polymorphisms for complex diseases: apolipoprotein E and Alzheimer disease. Neurogenetics 1997;1:3-11.

23. Schwartz PJ et al. Genotype-Phenotype correlation in the long-QT syndrome: gene-specific triggers for life threatening arrhythmias. Circulation 2001;103:89-95.

24. Poirier J et al. Apolipoprotein E4 allele as a predictor pf cholinergic deficits and treatment outcome in Alzheimer disease. Proc Acad Sci USA 1995;92:12260-4.

25. Weatherall DJ. Genomics and Global Health: Time for Reappraisal. Science 2003;32:597-598.

26. Sellers TA. Review of proteomics with application to genetic epidemiology. Gen Epidem 2003;24:83-98.

27. Preston RJ. Molecular epidemiology potential impacts on the assessment of public health. Rev Mut Res 2003;543:121-124.

28. Collins FS, Green ED, Guttmacher AE. A vision for the future of genomics research. Nature 2003;422:835-847.

29. Guttmacher AE, Collins PS. Welcome to the Genomic Era. N Engl J Med 2003;349:996-998.